Quantcast
Home » News
Home » News

Allergan tells shareholders to reject Valeant deal

Published June 23, 2014 9:54 am
This is an archived article that was published on sltrib.com in 2014, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

New York • Allergan, maker of Botox, said Monday that Valeant Pharmaceuticals' hostile takeover bid for the company is "grossly inadequate" and urged shareholders to reject it.

Allergan said the $53 billion bid from Valeant undervalues the company and is not in the best interest of Allergan's shareholders.

Valeant, a Canadian drugmaker, first offered to buy Irvine, Calif.-based Allergan Inc. in April. It has increased its original bid of about $45.6 billion several times, only to be rejected. Valeant teamed up with activist investor Bill Ackman's Pershing Square Capital Management for the bid.



On Friday, Valeant said it was taking its deal directly to Allergan shareholders and allowing them to trade in their stock for 0.83 shares of Valeant and $72 in cash, or another combination.

Allergan's CEO David E.I. Pyott said in a statement that the company can increase shareholder value more than Valeant's bid can.

Shares of Allergan slipped 31 cents to $165.01 in morning trading Monday. Valeant Pharmaceuticals International Inc. shares fell $1.26 to $120.67 in morning trading.

 

 

 

USER COMMENTS
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
comments powered by Disqus